Previous 10 | Next 10 |
2023-11-27 13:13:29 ET U.S. President Joe Biden plans to invoke the Defense Production Act of 1950 to build up domestic production of essential drugs, as one of the many actions announced during the first meeting of his new supply chain resilience council. The Cold War-era federal l...
First cystic fibrosis patient in Phase 1b study successfully completed two administrations of ARCT-032 On track to share interim Phase 1b data in H1 2024 Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stag...
2023-11-22 02:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-17 03:01:07 ET Summary Arcturus Therapeutics is a biotech firm focused on mRNA vaccine development and delivery technologies. The company's core investment thesis is centered around its cutting-edge research and its ability to derive revenue from its collaborations. Th...
2023-11-17 01:06:56 ET Summary The article provides an investment overview of Arcutus, offering insights and analysis, and ways of thinking about the investment opportunity. Arcutus is an mRNA specialist developer with no approved products to date - the company missed out on the C...
2023-11-15 05:06:44 ET Related stories: Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Call Transcript Cellectis SA (CLLS) Q3 2023 Earnings Call Transcript JD.com: Catch The Falling Knife Again? Better Think Twice (Rating Downgrade) Tiger Global ...
2023-11-14 20:38:06 ET Therapeutics Holdings Inc. (ARCT) Q3 2023 Earnings Conference Call November 15, 2023, 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public Relations, Marketing Joseph Payne - President and Chief E...
2023-11-14 17:54:03 ET Gainers: Solid Biosciences ( SLDB ) +34% . CorMedix ( CRMD ) +20% . Arcturus Therapeutics ( ARCT ) +14% . Frequency Electronics ( FEIM ) +8% . Collective Audience ( CAUD ) +7% . Lose...
2023-11-14 16:03:50 ET More on Arcturus Therapeutics Arcturus: Interim Readout Of Rare Disease Data In Coming Months Arcturus: mRNA Therapies For Rare Diseases Accelerate Towards Proof Of Concept Arcturus Therapeutics Q3 2023 Earnings Preview Arcturus up 5% a...
Expected cash runway extended to the end of 2026 $35 million milestone achieved under CSL collaboration ARCT-154 remains on track for Japan-NDA approval in December Enrollment target reached in Phase 3 bivalent COVID vaccine comparison trial Enrollment initiated in...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...